Scarica l'app Stockscreener
128.60
0.05%
0.06
Dopo l'orario di chiusura:
128.60
Precedente Chiudi:
$128.54
Aprire:
$128.77
Volume 24 ore:
1.17M
Relative Volume:
0.52
Capitalizzazione di mercato:
$13.67B
Reddito:
$612.78M
Utile/perdita netta:
$-86.37M
Rapporto P/E:
-147.82
EPS:
-0.87
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
+0.61%
1M Prestazione:
+1.66%
6M Prestazione:
+69.90%
1 anno Prestazione:
+75.49%
Intervallo 1D:
$128.52
$128.77
Intervallo di 1 settimana:
$127.91
$128.77
Portata 52W:
$62.78
$128.77
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Nome
Intra Cellular Therapies Inc
Settore
Telefono
(646) 440-9333
Indirizzo
135 ROUTE 202/206, BEDMINSTER, NY
Confronta ITCI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-31 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-11 | Iniziato | TD Cowen | Outperform |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2022-08-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-22 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Iniziato | Goldman | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-10 | Iniziato | Goldman | Buy |
| 2020-02-20 | Iniziato | Evercore ISI | Outperform |
| 2020-01-31 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-12 | Iniziato | Jefferies | Buy |
| 2018-02-26 | Iniziato | JP Morgan | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-11-08 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-09-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-09-29 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-09-29 | Downgrade | SunTrust | Buy → Neutral |
Mostra tutto
Intra Cellular Therapies Inc Borsa (ITCI) Ultime notizie
Intra-Cellular: Q4 Earnings Snapshot - CTPost
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
CAPLYTA’s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic Therapy | DelveInsight - GlobeNewswire Inc.
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by TimesSquare Capital Management LLC - MarketBeat
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
Intra-Cellular Therapies, Inc. SEC 10-K Report - TradingView
Form 10-K Intra-Cellular Therapies For: Dec 31 - StreetInsider.com
Intra-Cellular: Q4 Earnings Snapshot -February 21, 2025 at 08:18 am EST - Marketscreener.com
Intra-Cellular Therapies Q4 Net Loss Narrows, Revenue Rises -February 21, 2025 at 08:17 am EST - Marketscreener.com
Earnings Flash (ITCI) Intra-Cellular Therapies Posts Q4 Net Loss $0.16 a Share, vs. FactSet Est of $0.07 Loss - Marketscreener.com
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Principal Financial Group Inc. Reduces Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Savant Capital LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 12-Month HighWhat's Next? - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Update - MarketBeat
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat - MSN
StockNews.com Begins Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Quantum Private Wealth LLC - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Reaches New 1-Year HighHere's What Happened - MarketBeat
(ITCI) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Intra-Cellular Therapies Stock Soars to All-Time High of $128.01 - MSN
Rep. Josh Gottheimer Sells Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock - MarketBeat
Legato Capital Management LLC Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
abrdn plc Has $19.13 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Lessened by Calamos Advisors LLC - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Growth in Short Interest - MarketBeat
UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating - Marketscreener.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by China Universal Asset Management Co. Ltd. - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
KBC Group NV Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Intra Cellular Therapies Inc Azioni (ITCI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.72%
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):